BioAtla, Inc

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioAtla reports positive trial results and financial stability in Q4

BioAtla's Q4 2022 earnings call highlighted positive trial results, strong financial position, and progress in clinical development efforts
While facing challenges such as increased R&D expenses and enrollment hurdles, the company remains focused on innovation and patient safety
Opportunities lie in leveraging dosing regimens for enhanced efficacy, responding to patient needs, and updating stakeholders on future advancements

BioAtla reports positive clinical responses and solid financial position

BioAtla showcased strong clinical progress in Phase 2 trials, with positive responses in various cancer indications. Despite financial losses, the company maintains a solid cash position. Challenges lie in optimizing dosing and balancing characteristics in combination therapies, while opportunities exist in furthering combination therapy research and FDA interactions.

BioAtla reports progress in novel cancer therapies and financial stability

BioAtla is making significant strides in developing novel therapies for solid tumor types with high unmet medical needs.
The company's financial position is stable with plans to fund operations into 2025 and explore strategic partnerships.
Challenges include managing R&D expenses, rolling out liquid biopsy to other indications, and optimizing combination therapy approaches.
Opportunities lie in potential corporate development, strategic partnerships, and expanding treatment options with promising combination therapies.

BioAtla reports positive clinical trial results and strong financial position

BioAtla showcased promising clinical trial results for BA3011 and BA3021, with a focus on delivering innovative therapies for cancer treatment. Despite increased expenses and a net loss in Q3 2023, the company maintains a strong financial position and aims to maximize shareholder value through strategic collaborations and advancements in its pipeline.

BioAtla reports strong clinical progress and financial review in Q4

BioAtla's Q4 2023 earnings call highlighted substantial progress in clinical programs, financial performance, and strategic plans for future growth.
The company's focus on advancing CAB programs, innovative therapies, and collaborations underscores its commitment to driving clinical and commercial success.
While facing challenges in regulatory processes and trial execution, BioAtla remains well-positioned to leverage opportunities for market expansion and therapeutic innovation.

BioAtla reports positive clinical data and financial progress in Q1 2024 earnings call

BioAtla's Q1 2024 Earnings Call showcased positive clinical data, financial improvements, and strategic advancements in its pipeline.
The company's focus on safety, enthusiasm from leadership, and plans for future trials indicate a promising outlook for its drug development programs.
While facing challenges in differentiation, safety management, and financial sustainability, BioAtla remains poised to capitalize on market opportunities and collaborations.

BioAtla reports robust Q3 earnings with promising oncology pipeline progress

BioAtla's Q3 2024 earnings call highlighted strong financial performance and significant advancements in their oncology pipeline, supported by positive clinical data and regulatory feedback.
The company's focus on key compounds like ozuriftamab vedotin and evalstotug in various cancer types positions them well for future growth and potential commercial success.
While challenges in clinical trial execution and regulatory complexities exist, BioAtla has opportunities to capitalize on FDA support, expand indications, and drive innovation in precision oncology.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Coastal Insurance Corp

Alibaba

Baidu

Shift4 Payments

Hudson Pacific Properties

JD.com

Molina Healthcare

Olaplex Holdings

The RealReal

After the famous ‘Big Short' investor Michael Burry abandoned his 2023 bet against the semiconductor industry – though, interestingly, the short position may not have been wrong, only poorly timed – he again stirred controversy with his persistent bullishness about Chinese stocks.

‘Big Short' Michael Burry stock portfolio update

BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call.

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Ozuriftamab Vedotin shows promising Phase 2 results and received FDA Fast Track Designation, enhancing its potential.

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.

BioAtla: Numerous Catalysts Coming In Q4

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.

Michael Burry buys 634,000 shares of this $1 penny stock

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Operator Good day, everyone.

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Immuneering Corp

Rockwell Medical

With the third quarter in full swing, the bulls have not lost their grip on equities.

3 Penny Stocks With 735% Average Upside, According to Wall Street

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.

BioAtla to Participate in the Jefferies Global Healthcare Conference

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, Chief Executive Officer and Co-Founder Eric Sievers – Chief Medical Officer Sheri Lydick – Chief Commercial Officer Richard Waldron – Chief Financial Officer Conference Call Participants Brian Cheng – JPMorgan Dev Prasad – Jefferies Kaveri Pohlman – BTIG Arthur He – H.C. Wainwright Tony Butler – EF Hutton Operator Greetings and welcome to the BioAtla First Quarter 2024 Earnings Call.

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and provided highlights on its clinical programs.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

BioAtla to Participate in the Citizens JMP Life Sciences Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy. Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules. BioAtla has promising pipeline candidates, including mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, with ongoing clinical studies.

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided highlights on its clinical programs.

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024.

News for BioAtla, Inc Stock (BCAB)